Superworth

Zoetis price to free cash flow ZTS

Market value divided by free cash flow over the last twelve months, since 2014.

Today, Oct 23, 2026
14.2×
10-year median
46.6×
Against its 10-year history
2nd
percentile: 0 is its lowest day, 100 its highest
10-year range
12.2× to 69.0×
Peer median
21.5×

Zoetis' price to free cash flow is 14.2× as of Oct 23, 2026.

That is below its ten-year median of 46.6×, lower than on 98% of days in the last ten years.

Over that time it ranged from 12.2× in Oct 2026 to 69.0× in Sep 2023.

The median for 10 healthcare stocks of a similar size is 21.5×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far14.2×12.2×25.1×
202524.8×23.3×33.5×
202432.2×32.2×61.2×
202360.7×49.9×69.0×
202253.9×46.5×57.9×
202164.5×41.4×64.5×
202051.6×35.9×54.5×
201946.5×26.5×46.5×
201826.5×25.6×47.4×
201742.7×40.7×59.0×
201656.5×34.8×59.4×
201541.2×38.6×64.4×
201461.7×28.6×97.0×

Against its peers

Companies in Healthcare nearest Zoetis' size, closest first, today.

CompanyPrice to free cash flow
ZTSZoetis14.2×
MTDMettler-Toledo International38.7×
CNCCentene3.9×
GEHCGE HealthCare Technologies20.4×
RMDResMed22.1×
RPRXRoyalty Pharma13.3×
BIIBBiogen13.7×
ALNYAlnylam Pharmaceuticals37.8×
DXCMDexCom20.9×
WSTWest Pharmaceutical Services63.2×
ILMNIllumina43.7×
Peer median21.5×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Zoetis

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.